Shedding Light on the Dark Genome: Insights into the Genetic, CRISPR-based, and Pharmacological Dependencies of Human Cancers and Disease Aggressiveness
Preprint
Abstract
Investigating the human genome is vital for identifying risk factors and devising effective therapies to combat genetic disorders and cancer. Despite the extensive knowledge of the “light genome”, the poorly understood “dark genome” remains understudied. In this study, we integrated data from 20,412 protein-coding genes in Pharos and 8,395 patient-derived tumours from The Cancer Genome Atlas (TCGA) to examine the genetic and pharmacological dependencies in human cancers and their treatment implications. We discovered that dark genes exhibited high mutation rates in certain cancers, similar to light genes. By combining the drug response profiles of cancer cells with cell fitness post-CRISPR-mediated gene knockout, we identified the crucial vulnerabilities associated with both dark and light genes. Our analysis also revealed that tumours harbouring dark gene mutations displayed worse overall and disease-free survival rates than those without such mutations. Furthermore, dark gene expression levels significantly influenced patient survival outcomes. Our findings demonstrated a similar distribution of genetic and pharmacological dependencies across the light and dark genomes, suggesting that targeting the dark genome holds promise for cancer treatment. This study underscores the need for ongoing research on the dark genome to better comprehend the underlying mechanisms of cancer and develop more effective therapies.Keywords
All Related Versions
- Published version: PLOS ONE, 18 (12), e0296029.
This publication has 80 references indexed in Scilit:
- Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compoundsSeminars in Cancer Biology, 2015
- RAI2: Linking Retinoic Acid Signaling with Metastasis SuppressionCancer Discovery, 2015
- Suppression of Early Hematogenous Dissemination of Human Breast Cancer Cells to Bone Marrow by Retinoic Acid–Induced 2Cancer Discovery, 2015
- Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexesNature Genetics, 2014
- TP53 oncomorphic mutations predict resistance to platinum- and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinomaInternational Journal of Oncology, 2014
- Multiple evidence strands suggest that there may be as few as 19 000 human protein-coding genesHuman Molecular Genetics, 2014
- Functionally Enigmatic Genes: A Case Study of the Brain IgnoromePLOS ONE, 2014
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cellsNucleic Acids Research, 2012
- Understanding survival analysis: Kaplan-Meier estimateInternational Journal of Ayurveda Research, 2010